2 / 25
Page 19
Notes:
conferenceseries
.com
Volume 6, Issue 6 (Suppl)
Med Aromat Plants
ISSN: 2167-0412 MAP, an open access journal
Herbals Summit 2017
October 18-20, 2017
October 18-20, 2017 Osaka, Japan
3
rd
Global Summit on
Herbals & Traditional Medicine
Efficacy, safety and dose finding trial of topical Jaungo application in atopic dermatitis patients: A
randomized, double-blind, placebo-controlled study
Younghee Yun
CY Pharmaceutical Co., Ltd., Republic of Korea
A
topic Dermatitis (AD) is a common pruritic inflammatory skin disease. In its chronic stage, hyperpigmentation,
excoriation, lichenification and dryness are the main symptoms. Jaungo comprises two herbs,
Lithospermi Radix
and
Angelica Gigantis Radix
and three carrier oils and is an approved herbal ointment for xerosis in Korea. In past preclinical
studies, we demonstrated that Jaungo had anti-inflammatory and anti-allergic activity. We conducted a randomized, double
blind, placebo-controlled, single-center trial with three parallel arms. Trial group-1 applies Jaungo twice a day, while trial
group-2 applies Jaungo and the placebo once a day, separately, and the placebo group applies the placebo twice a day, for a total
of 3 weeks each. Participants evaluated for eczema based on the eczema area and severity score, the scoring of atopic dermatitis
score, the dermatology life quality score, trans-epidermal water loss, total IgE level, eosinophil count and IL-17, IL-22 and
IFN-γ levels. The outcomes to evaluate the safety included Draize score and blood test. In total, 28 patients (82.4%) completed
the study. Significant decline of EASI scores in trial group-2 and placebo group was observed (p<0.05). There was significant
decline of SCORAD scores in trial group-1 and placebo group (p<0.05). However, patients in all groups showed decreased
TEWL and DLQI scores with no significant difference. No clinically relevant changes in laboratory values were observed except
IL-17. There was significant decline of IL-17 in all groups (p<0.05). Inter-group analysis showed no significant difference. No
serious adverse event was observed.
Biography
Younghee Yun has completed her PhD from College of Traditional Korean Medicine, Kyung Hee University in Korea. She has published more than 12 papers.
Currently she is the CEO of CY Pharmaceutical Co., Ltd. Her main interest is atopic dermatitis, allergic skin disease and pharmacological action of herbal medicine.
younghee.yun@hanmail.netYounghee Yun, Med Aromat Plants 2017, 6:6 (Suppl)
DOI: 10.4172/2167-0412-C1-014